Matinas BioPharma Holdings, Inc. - MTNB Total Company Value-to-Revenue Ratio

Matinas BioPharma Holdings, Inc. (MTNB) - corporate logo

Patents for LNC technology and strict FDA oversight create a high barrier to entry for competitors for Matinas BioPharma (MTNB). The drug delivery expert team is retained through cutting-edge research and comprehensive benefits packages. The innovative platform converts injections into tablets, simplifying the treatment of infections. The price-to-sales multiple trend clearly demonstrates this potential, and 0.00 reflects the latest level of the metric.

MTNB Matinas BioPharma Holdings: Enterprise Value-to-Revenue Ratio in the range 11/23/2025 - 11/20/2026

Matinas BioPharma - analytical breakdowns and key metrics (MTNB)

Manufactured product of Matinas BioPharma Holdings Inc.

The EV/Sales ratio is used for an objective valuation of Matinas BioPharma (MTNB), correlating the total enterprise value, including net debt, with the volume of generated revenue. By analyzing the EV/Sales historical trend, an investor can gauge market expectations for the commercialization of Matinas BioPharma nanocochleates, assessing how effectively the transition to oral drug formulations is being capitalized into the company's valuation relative to its current sales.

Competitor analysis for Matinas BioPharma

ASND: Enterprise Value-to-Revenue Ratio|MDGL: EV/Sales Multiple|CORT - Total Company Value-to-Revenue Ratio|Enterprise Value-to-Revenue Ratio Rhythm Corp|Akero Corp (AKRO) - Total Company Value-to-Revenue Ratio|Enterprise Value-to-Revenue Ratio metsera.com (MTSR)|Company Value to Revenue moonlaketx.com MLTX|EV/Sales Multiple CRNX (Crinetics Pharmaceuticals, Inc.)|NAMS: Company Value to Revenue Ratio|SLNO - Enterprise Value-to-Revenue Ratio|Amicus Pharma (FOLD) - Company Value to Revenue|ETNB: EV/Sales Multiple|AGIO - Total Company Value-to-Revenue Ratio|Company Value to Revenue GPCR|Enterprise Value-to-Revenue Multiple MiMedx MDXG|Enterprise Value-to-Revenue Ratio Rezolute Corp (RZLT)|Company Value to Revenue Lexicon Corp LXRX|Enterprise Value-to-Revenue Ratio MBX Biosciences, Inc. MBX|EV/Sales Multiple altimmune.com ALT|AARD - Enterprise Value-to-Revenue Ratio|Sagimet - Enterprise Value-to-Revenue Coefficient|BioAge Labs Inc. (BIOA) - Enterprise Value-to-Revenue Ratio|Enterprise Value to Sales Volume BMEA (Biomea Fusion, Inc.)|QNCX (quincetx.com) - EV/Sales Multiple|GUTS: Business Value to Revenue|Enterprise Value-to-Revenue Ratio vtvtherapeutics.com (VTVT)|ATPC (Agape ATP) - Business Value to Revenue|Enterprise Value-to-Revenue Ratio Pluristem Therapeutics PLUR|SYBX: Company Value to Revenue Ratio|lipocine.com - EV/Sales Multiple|Spruce Biosciences, Inc. (SPRB) - Company Value to Revenue|GLTO: EV/Sales Multiple|Enterprise Value-to-Revenue Multiple Carmell Corp. (CTCX)|LUMO (Lumos Therapeutics) - EV/Sales Multiple|Organovo Corp (ONVO) - Total Company Value-to-Revenue Ratio|Enterprise Value-to-Revenue Ratio Radius Recycling (RDUS)